• Immunogenicity Assessment

    • Therapeutic In Silico Services
      • ISPRIâ„¢ Website
      • ISPRI Downselectâ„¢
      • ISPRI Quantifyâ„¢
      • ISPRI Analyzeâ„¢
      • ISPRI Evaluateâ„¢
      • ISPRI-HCPâ„¢
      • ISPRI Designâ„¢
      • PANDA® Screening
    • Vaccine In Silico Services
      • iVAXâ„¢
      • EpiCCâ„¢
      • Ancer®
      • PreVAXâ„¢
    • Lab Services
      • All In Vitro Assays
      • Generic Peptide PANDA® Assays
    • Consulting Services
      • Trusted Expert Advice (TEA)
      • IRA / ISI Regulatory Writing Support
    • Why Immunogenicity Risk Assessment?
    • Why EpiVax?
  • About Us
    • Company History
    • Leadership
    • Careers
  • Press
    • News
    • Events
    • Publications
    • Blog
  • Contact Us
Antigen-specific tolerance induction by Tregitopes in vivo

Antigen-specific tolerance induction by Tregitopes in vivo

by Adam | Oct 21, 2016

Tregitope Applications to Tolerance Induction in Autoimmune Disease and Therapeutic Protein Immunogenicity

Tregitope Applications to Tolerance Induction in Autoimmune Disease and Therapeutic Protein Immunogenicity

by Adam | Oct 21, 2016

Albumin Delivery of Tregitope Peptides for Tolerance Induction in Autoimmunity and Inflammatory Disease

Albumin Delivery of Tregitope Peptides for Tolerance Induction in Autoimmunity and Inflammatory Disease

by Adam | Oct 21, 2016

In silico High Throughput Pre-clinical Determination of Monoclonal Antibody Immunogenicity

In silico High Throughput Pre-clinical Determination of Monoclonal Antibody Immunogenicity

by Adam | Oct 21, 2016

Immunogenic Biologics: Validation of Screening, Deimmunization and Tolerization Approaches

Immunogenic Biologics: Validation of Screening, Deimmunization and Tolerization Approaches

by Adam | Oct 21, 2016

« Older Entries
Next Entries »

Recent Posts

  • EpiVax Announces Laboratory Expansion and Streamlined, NAM-Centric In Vitro Services    
  • Replacing Animal Models with Human-Relevant New Approach Methodologies (NAMs) for Immunogenicity in Clinic
  • EpiVax Enters its Next Chapter with SV Health Investors
  • Immunogenicity Risk Assessment Outputs to Drive a Streamlined, Risk-Based Preclinical and Clinical Strategy
  • Immunogenicity Risk Assessment Outputs to Drive a Streamlined, Risk-Based Preclinical and Clinical Strategy

Recent Comments

No comments to show.

Explore

Therapeutic In Silico Services

Vaccine In Silico Services

Lab Services

Consulting

LinkedIn

About Us

Careers

News

Events

Publications

Contact Us

This website uses cookies and similar technologies to collect information about your website experience for advertising, analytics, and other purposes as described in our Privacy Policy.